CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This study is testing an off-the-shelf (allogeneic) CAR-T cell therapy — immune cells engineered using CRISPR gene-editing to target a protein called BCMA found on myeloma cells — in patients with multiple myeloma that has relapsed (come back) or is refractory (not responding) to multiple prior treatments. Unlike standard CAR-T, these cells come from a donor rather than the patient. **You may be eligible if...** - You have confirmed multiple myeloma that has relapsed or is refractory - You have already tried at least 3 prior treatment regimens, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody - Your general health is reasonably good (ECOG 0-1) - Your organ function (blood, liver, kidneys, heart, lungs) is adequate **You may NOT be eligible if...** - You have previously received CAR-T cell therapy for any target - You had an autologous stem cell transplant less than 6 weeks ago, or an allogeneic transplant less than 6 months ago - You have HIV, active hepatitis B or C, or known active brain involvement by myeloma - You have had a seizure or stroke in the past 6 months - You have received a live vaccine within 4 weeks before starting treatment Talk to your doctor to see if this trial is right for you.